Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy in Diabetic Nephropathy Patients: A Clinical Trial — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(1 site)
Indonesia
Dr. Sardjito General Hospital, Yogyakarta Age range
30 Years – 65 Years
Last updated February 2026